You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

KMT2A-rearranged

Showing 1 - 25 of 232
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia Trial (Blinatumomab)

Not yet recruiting
  • Acute Lymphoblastic Leukemia
  • Mixed Phenotype Acute Leukemia
  • (no location specified)
Apr 7, 2022

AML, AML With Mutated NPM1, Hematologic Malignancy Trial (Ziftomenib, Fludarabine, Idarubicin)

Not yet recruiting
  • AML
  • +11 more
  • (no location specified)
Aug 14, 2023

Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation Trial (Biospecimen Collection, Bone

Not yet recruiting
  • Acute Myeloid Leukemia With KMT2A Rearrangement
  • Acute Myeloid Leukemia With NPM1 Mutation
  • Biospecimen Collection
  • +7 more
  • (no location specified)
Jun 1, 2023

Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia

Not yet recruiting
  • Recurrent Acute Leukemia of Ambiguous Lineage
  • +5 more
  • Biospecimen Collection
  • +12 more
  • (no location specified)
Mar 8, 2023

B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Chronic

Terminated
  • B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged
  • +16 more
  • Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
May 28, 2021

Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation Trial (Ziftomenib, Venetoclax,

Not yet recruiting
  • Acute Myeloid Leukemia
  • +10 more
  • (no location specified)
Feb 17, 2023

Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia Trial in Kansas City, Cincinnati

Recruiting
  • Relapsed/Refractory Leukemias
  • +4 more
  • Kansas City, Missouri
  • +1 more
Jul 18, 2022

Non Small Cell Lung Cancer, Metastatic, Recurrent Trial in United States (Lorlatinib, Ramucirumab)

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Middletown, New Jersey
  • +5 more
Aug 17, 2023

Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL, Infants With Very High Risk KMT2A B-ALL, Patients With CNS

Active, not recruiting
  • Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL
  • +2 more
  • Murine CART19
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jan 11, 2022

People Who Have Genetic Changes and Features of Autism: Simons

Recruiting
  • 16P11.2 Deletion Syndrome
  • +184 more
    • New York, New York
    • +1 more
    Jan 6, 2023

    Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia Trial in Worldwide

    Active, not recruiting
    Has Results
    • Acute Leukemia of Ambiguous Lineage
    • +2 more
    • Birmingham, Alabama
    • +173 more
    Nov 16, 2021

    ALK-positive NSCLC (NSCLC), RET-positive NSCLC (NSCLC), RET-positive Thyroid Cancer Trial in Irvine, Boston (Alectinib)

    Terminated
    Has Results
    • ALK-positive Non-small Cell Lung Cancer (NSCLC)
    • +2 more
    • Irvine, California
    • +3 more
    Aug 30, 2021

    Solid Tumor, Medullary Thyroid Cancer Trial in China (Selpercatinib)

    Active, not recruiting
    Has Results
    • Solid Tumor
    • Medullary Thyroid Cancer
    • Guangzhou, Guangdong, China
    • +12 more
    May 9, 2022

    Intrahepatic Cholangiocarcinoma (ICC) Trial in China (ICP-192)

    Recruiting
    • Intrahepatic Cholangiocarcinoma (ICC)
    • Hefei, Anhui, China
    • +43 more
    Dec 23, 2022

    Non Hodgkin Lymphoma, Lymphoma, B-Cell, High-grade B-cell Lymphoma Trial in Belgium, Netherlands (DA-EPOCH-R followed by

    Active, not recruiting
    • Non Hodgkin Lymphoma
    • +4 more
    • DA-EPOCH-R followed by Nivolumab
    • Antwerpen, Belgium
    • +23 more
    Mar 23, 2022

    High-grade B-cell Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell Trial in Busan, Seoul (Sepantronium Bromide)

    Not yet recruiting
    • High-grade B-cell Lymphoma
    • +8 more
    • Sepantronium Bromide
    • Busan, Korea, Republic of
    • +5 more
    Feb 27, 2022

    Anaplastic Lymphoma Kinase (ALK), NSCLC Trial in Worldwide (LDK378, AUY922)

    Completed
    • Anaplastic Lymphoma Kinase (ALK)
    • Non-small Cell Lung Cancer
    • Aurora, Colorado
    • +7 more
    Dec 16, 2020

    NSCLC Trial in Worldwide (Ceritinib, pemetrexed, docetaxel)

    Active, not recruiting
    Has Results
    • Non-Small Cell Lung Cancer
    • Fayetteville, Arkansas
    • +96 more
    Dec 19, 2022

    NSCLC Trial in Davis, San Francisco (Ceritinib, Trametinib)

    Terminated
    • Non-small Cell Lung Cancer
    • Davis, California
    • +1 more
    Dec 22, 2022

    NSCLC Trial in Worldwide (ceritinib)

    Completed
    • Non-Small Cell Lung Cancer
    • Fayetteville, Arkansas
    • +72 more
    Feb 7, 2022

    NSCLC Trial in Worldwide (Ceritinib, Pemetrexed, Cisplatin)

    Active, not recruiting
    Has Results
    • Non-Small Cell Lung Cancer
    • Woolloongabba, Queensland, Australia
    • +131 more
    Oct 24, 2022

    Acute Leukemias, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Worldwide (JNJ-75276617)

    Recruiting
    • Acute Leukemias
    • +2 more
    • Duarte, California
    • +28 more
    Jan 27, 2023

    Leukemia, Myeloid, Acute Trial in Worldwide (JNJ-75276617, Venetoclax (VEN), Azacitidine (AZA))

    Recruiting
    • Leukemia, Myeloid, Acute
    • Birmingham, Alabama
    • +30 more
    Aug 11, 2022

    Non Small Cell Lung Cancer Trial in Changsha (IBI-322 Plus Lenvatinib and Platinum)

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • IBI-322 Plus Lenvatinib and Platinum
    • Changsha, Hunan, China
      Hunan Cancer hospital
    Jul 14, 2022

    NSCLC Stage IIIB, ALK Gene Mutation Trial in Mexico City (Alectinib Oral Product)

    Recruiting
    • Non-small Cell Lung Cancer Stage IIIB
    • ALK Gene Mutation
    • Alectinib Oral Product
    • Mexico City, Mexico
      Thoracic Oncology Unit and Personalized Medicine Laboratory, Ins
    Jan 26, 2023